Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on the Effects of EH-301, N-Acetylcysteine, and Riluzole in Patients with Amyotrophic Lateral Sclerosis (ALS)

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for Amyotrophic Lateral Sclerosis (ALS), a progressive disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and loss of motor function. The study will evaluate a combination therapy that includes N-Acetylcysteine (NAC), a substance known for its antioxidant properties, and EH-301, alongside the medication Riluzole, which is commonly used to treat ALS. The purpose of the study is to assess the safety and effectiveness of this combined treatment in slowing down the progression of ALS.

Participants in the study will be randomly assigned to receive either the combination therapy or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure that the results are unbiased. The treatment will be administered orally, and participants will be monitored over a period of time to observe any changes in their condition, particularly focusing on their ability to perform daily activities and their overall quality of life.

The study aims to gather valuable information on how the combination of NAC, EH-301, and Riluzole affects the progression of ALS. By using the ALS Functional Rating Scale-Revised (ALSFRS-R), researchers will evaluate changes in participants' physical abilities. Additionally, the study will look at other factors such as muscle strength, respiratory function, and survival rates. The findings from this study could contribute to developing more effective treatments for individuals living with ALS.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, an initial visit is scheduled. During this visit, eligibility is confirmed based on specific criteria, such as age, diagnosis of amyotrophic lateral sclerosis (ALS), and current health status.

    A detailed explanation of the study procedures, potential risks, and benefits is provided. Written informed consent is obtained before any study-related activities begin.

  2. Step 2

    Baseline assessment

    A comprehensive assessment is conducted to establish baseline health status. This includes measuring muscle strength, respiratory function, and quality of life using specific scales.

    The ALS Functional Rating Scale-Revised (ALSFRS-R) is used to evaluate the current level of function.

  3. Step 3

    Medication regimen

    Participants are required to continue taking riluzole at a dose of 50 mg twice daily. This medication should have been taken for at least 30 days prior to the start of the study and will continue throughout the trial.

    In addition to riluzole, participants will receive either a combination of N-acetylcysteine (NAC) and EH-301 or a placebo. The specific dosage and frequency of these additional treatments are determined by the study protocol.

  4. Step 4

    Follow-up visits

    Regular follow-up visits are scheduled to monitor health status and any changes in symptoms. These visits include assessments similar to the baseline assessment, focusing on muscle strength, respiratory function, and quality of life.

    Adjustments to the treatment regimen may be made based on the participant's response and any side effects experienced.

  5. Step 5

    Final assessment

    At the end of the study period, a final assessment is conducted. This includes a comprehensive evaluation of the participant's health status and any changes in the ALSFRS-R score.

    The results of the study are analyzed to determine the effectiveness and safety of the treatment regimen.

Who can join the trial?

9 criteria

  • Patients must be diagnosed with Amyotrophic Lateral Sclerosis (ALS) according to specific medical guidelines known as the Gold Coast criteria.
  • The disease must have been present for 18 months or less.
  • Participants must be between 18 and 75 years old.
  • The ALS Functional Rating Scale-Revised (ALSFRS-R) score, which measures the ability to perform daily activities, must be 30 or higher across all 12 categories.
  • The Forced Vital Capacity (FVC), a test that measures lung function, must be 70% or higher.
  • Participants must be taking a medication called Riluzole (50 mg twice daily) for at least 30 days before starting the study and continue this dose until the study ends.
  • Participants must be willing and able to follow the study's requirements.
  • Participants must sign a written consent form before any study-related procedures begin.
  • Women of childbearing age must agree to use specific contraceptive methods starting 30 days before taking the study medication and continue throughout the study. Acceptable methods include non-hormonal intrauterine device (IUD), barrier methods like condoms, surgical sterilization, having a partner who has had a vasectomy, or abstaining from sexual intercourse.

Who cannot join the trial?

4 criteria

  • Patients who are not able to walk or move around on their own.
  • Patients who have not been diagnosed with Amyotrophic Lateral Sclerosis (ALS) using the ALS Functional Rating Scale-Revised (ALSFRS-R) score.
  • Patients who are under the age of 18 or over the age of 75.
  • Patients who are part of a vulnerable population, such as those who cannot give consent for themselves.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • EH-301

    is a medication being studied for its potential to help people with Amyotrophic Lateral Sclerosis (ALS), a condition that affects the nerves and muscles. In this trial, EH-301 is being tested to see if it can slow down the progression of ALS when used together with other treatments. The goal is to find out if EH-301 can help improve or maintain the ability to perform daily activities, which is often measured by a specific scale used for ALS patients.

  • N-Acetylcysteine

    , often called NAC, is a supplement that is being tested in this trial for its potential benefits in treating ALS. NAC is known for its antioxidant properties, which means it might help protect cells from damage. In this study, researchers are looking to see if NAC can help slow down the progression of ALS when used in combination with other treatments. The hope is that NAC can help patients maintain their ability to perform everyday tasks for a longer period.

  • Riluzole

    is a medication that is already used to treat ALS. It works by affecting the nerve cells in the brain and spinal cord, which can help slow down the progression of the disease. In this trial, Riluzole is being used as part of a combination therapy to see if it can be even more effective when used together with other treatments like EH-301 and NAC. The aim is to see if this combination can help patients maintain their physical abilities and improve their quality of life.

What is already known about the treatment

  • EH-301

    EH-301 is administered orally and is currently being studied in clinical trials for its potential use in treating Amyotrophic Lateral Sclerosis (ALS). It is not yet widely recognized in medical literature as a standard treatment. The main therapeutic indication for EH-301 is to slow the progression of ALS, a condition that affects nerve cells in the brain and spinal cord. At the molecular level, EH-301 is believed to work by protecting nerve cells from damage, although the exact mechanism is still under investigation. It is classified as a neuroprotective agent.

  • N-Acetylcysteine (NAC)

    N-Acetylcysteine, or NAC, is taken orally and is being evaluated in clinical trials for its effectiveness in treating ALS. While NAC is already used in medicine for other conditions, its role in ALS is still being explored. The primary therapeutic indication for NAC in this context is to help slow the progression of ALS. NAC works at the molecular level by replenishing levels of glutathione, a powerful antioxidant that helps protect cells from damage. It is pharmacologically classified as a mucolytic agent and antioxidant.

  • Riluzole

    Riluzole is an oral medication that is currently approved and used in the treatment of ALS. It is well-documented in medical literature as a standard treatment for this condition. The main therapeutic indication for Riluzole is to extend survival and slow the progression of ALS. At the molecular level, Riluzole works by decreasing the release of glutamate, a neurotransmitter that can be harmful in excessive amounts. It is classified as a glutamate release inhibitor.

Investigated diseases

Amyotrophic Lateral Sclerosis (ALS) – Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. It leads to the gradual degeneration and death of motor neurons, which are responsible for controlling voluntary muscles. As these neurons die, the brain loses the ability to initiate and control muscle movement. This results in muscle weakness and atrophy, often starting in the limbs and spreading to other parts of the body. Over time, individuals with ALS may experience difficulty speaking, swallowing, and breathing. The progression of the disease varies among individuals, but it typically leads to increasing physical disability.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-519857-13-00Protocol codeNADALS-001-ALS -2021Estimated enrolment90 patientsSponsorAsociacion Instituto Biogipuzkoa

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).